Tid: 2018-12-03 Kl 13:30
Plats: Medicon Village, Lecture Hall (Hörsalen), Scheelevägen, Lund
Kontakt: Malin Lindstedt, firstname.lastname@example.org
Title: “A tetanus-way of boosting T cell responses”
Speaker: Sara Mangsbo, Pharmaceutical Biosciences, University of Uppsala,
“Immune complexes can greatly potentiate cross presentation and CD8 T cell activation. Herein a drug development project makes us of a drug design promoting antibody-drug complex formation in vivo to mediate improved T cell responses against a given antigen within the drug formulation”.
Sara Mangsbo is Senior associate lecturer in antibody drugs and Assoc. professor at Pharmaceutical Biosciences at Uppsala University. She is also founder and previous CSO of Immuneed AB and currently Chief Development Officer of Ultimovacs AS/AB. Sara defended her thesis in 2010 around local immune modulation using TLR ligand stimulation and check-point blocking antibodies to study immune responses in a preclinical model of bladder cancer. She later continued with a postdoctoral period in Professor Melief and Professor Ossendorp’s laboratory at LUMC in the Netherlands. The project involved the use of peptide vaccines in an immune complex formulation to enhance antigen delivery to dendritic cells.
She has continued to work on cancer immunotherapy in Sweden with a translational focus, actively pursuing to move the research projects into clinical use. She is also active in the antibody therapy field and has been part in the preclinical development project of ADC1013 that is now in clinical trial. Sara is currently running a project on the SciLife DDD platform together with Helena Persson.
1. EAK Fletcher, W van Maren, R Cordfunke, J Dinkelaar, JDC Codee, G van der Marel, CJM Melief, F Ossendorp, JW Drijfhout, SM Mangsbo. Formation of immune-complexes with a tetanus-derived B cell epitope boosts human T cell responses to covalently-linked peptides in an ex-vivo blood loop system. Accepted in Journal of Immunology 2018.
2. Fletcher EAK, Eltahir M, Lindqvist F, Rieth J, Törnqvist G, Leja-Jarblad J, Mangsbo SM. Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics. Int Immunopharmacol. 2018 Jan;54:1-11.
3. Mangsbo SM, Fletcher EAK, van Maren WWC, Redeker A, Cordfunke RA, Dillmann I, Dinkelaar J, Ouchaou K, Codee JDC, van der Marel GA, Hoogerhout P, Melief CJM, Ossendorp F, Drijfhout JW. Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses. Mol Immunol. 2018 Jan;93:115-124
4. van Hooren L, Sandin LC, Moskalev I, Ellmark P, Dimberg A, Black P, Tötterman TH, Mangsbo SM. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer. Eur J Immunol. 2017 Feb;47(2):385-393. doi: 10.1002/eji.201646583. Epub 2016 Dec 13.
5. Mangsbo SM, Broos S, Fletcher E, Veitonmaki N, Furebring C, Dahlen E, Norlen P, Lindstedt M, Totterman TH, Ellmark P. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T cell dependent tumor immunity. Clin Cancer Res. 2015 Mar 1;21(5):1115-26.